Results of the DESTINY-CRC01 trial demonstrated durable responses in patients with previously treated HER2-positive mCRC (median progression-free survival 6.9 months, 95% CI = 4.1 months–not evaluable) [23], further supporting the use of conjugated mAbs in the targeted treatment of CRC in the adjuvant setting. Here, ERBB2 is linked to colorectal carcinoma.